Discussing Breast Cancer ASCO 2023 Highlights
Focusing on practice-changing studies with Dr. Stephanie Graff, Director of Breast Oncology, Associate Professor of Medicine, Lifespan Cancer Institute, Brown University. Covering three important studies
Key Points:
- NATALEE Phase III study of ribociclib (RIBO) + endocrine therapy (ET) in HR+ patients
- SONIA challenging the need for first-line use of a CDK4/6 Inhibitor in HR+ advanced breast cancer patients
- X-7/7 trial evaluating fixed-dose capecitabine compared to standard dose capecitabine in metastatic breast cancer
